SRPT241206P115000
- 6.60
- 0.000.00%
Sarepta Therapeutics Newsroom
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
Based On Its ROE, Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A High Quality Stock?
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
Sarepta Therapeutics Is Maintained at Sell by HC Wainwright & Co.
Sarepta Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $75
Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth Potential
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Trending Stocks This Week as Holiday Season Begins With Thanksgiving Break
Express News | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Price Target Lowered to $202 From $205 at Needham
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $215
RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies